U.S. drug industry hopes China deal ends stealth attack on IP

Innovator pharmaceutical manufacturers hope the new “phase one” U.S.-China trade deal will create a cease-fire in the stealth war on pharma IP in China.

The deal, announced Dec. 13, comes at the end of a year when Chinese IP practices have cut short patent exclusivity for at least five innovative drugs...